Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The market dynamics of Blood Coagulants revolve around elements such as the prevalence of bleeding issues, advancements in hemostatic remedies, regulatory considerations, and the aggressive landscape in the pharmaceutical enterprise. Understanding these dynamics is vital for stakeholders concerned with the development, manufacturing, and distribution of blood coagulation merchandise. The incidence of bleeding issues, along with hemophilia and von Willebrand's sickness, extensively affects market dynamics. As recognition grows and greater individuals are recognized, there is an increasing demand for powerful Blood Coagulants to manage and treat these situations. Ongoing advancements in hemostatic remedies contribute to the evolution of the Blood Coagulants market. Novel cures, which include gene remedies and extended half-life issue concentrates, aim to offer extra green and convenient options for people with bleeding disorders, influencing market dynamics.
An affected person-centric method is increasingly crucial in the Blood Coagulants market. Companies are focusing on growing remedies that offer ease of management, decreased treatment burden, and progressed nice of lifestyles for people with bleeding disorders, influencing market dynamics. The global growth of the blood coagulants market is motivated by the growing prognosis and recognition of bleeding problems worldwide. As healthcare infrastructure improves in rising markets, the demand for powerful blood coagulants is likely to grow, impacting market dynamics globally. The introduction of biosimilars and usual versions of Blood Coagulants contributes to market dynamics. Increased competition can result in price reductions, affecting market proportion and shaping the techniques of pharmaceutical companies. Technological improvements in manufacturing tactics play a pivotal role in market dynamics.
Pediatric hemostatic treatments represent a specialized phase in the market. Tailoring products for the pediatric populace, thinking about factors that include dosing, management, and safety, affects market dynamics as groups cope with the precise desires of more youthful patients with bleeding disorders. Economic factors, along with healthcare prices and affordability, affect market dynamics. Companies have to navigate pricing techniques that balance the price-effectiveness of Blood Coagulants with accessibility for an extensive range of individuals in need. The Blood Coagulants market faces demanding situations along with the improvement of inhibitors in sufferers, variability in man or woman responses, and the need for persistent innovation. Mitigating those risks is essential for sustained increase and fulfillment in a market targeted at offering existence-saving treatments for people with bleeding issues.
Blood Coagulants Market Highlights:
Middle East & Africa Blood Coagulants Market Overview
The Middle East & Africa Blood Coagulants Market is expected to grow USD 2.77 Billion at a CAGR 6.70% during the forcast period 2023 to 2030. Coagulation is the process, by which blood changes from a liquid to a gel, forming a blood clot. In general terms, coagulation is a process in which the blood forms clots to block and then heal a lesion/wound/cut and stop the bleeding.
The Middle East & Africa blood coagulants market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders.
In the Middle East and Sub-Saharan Africa, bleeding disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment. As per the study published in Blood Coagulation Fibrinolysis journal, 2016, it is reported that in the Yaoundé Hemophilia Treatment Center (HTC) of Cameroon multiple cases of hemophilia and von willebrand disease (VWD) have been registered According to the 2014 Annual Global Survey of World Federation of Hemophilia (WFH), in 2014 the total population of Egypt was 86,895,099 out of which 5,246 people were living with hemophilia, 513 were living with von willebrand disease, and 1,123 with other bleeding disorders. It is also reported that 4201 cases of hemophilia A were registered and among them 37% were under 4 years A research study published in Medicine journal in 2017 stated that hemophilia A is the most common type of hemophilia in Saudi Arabia and most dominant in male patients: 1 : 5000 to 10,000. Whereas, prevalence rate of hemophilia B: 1: 34,500 male patients
The Middle East & Africa blood coagulants market growth is majorly attributed to increasing prevalence of the bleeding disorders, rising funding, healthcare insurance coverage, and awareness programs for bleeding disorders. On the other hand, there are certain factors that also hinder the growth of this market such as lack of R&D capabilities in the regions, presence of counterfeit drugs, and lack of awareness in most of the parts of developing and underdeveloped countries in the region.
Figure- MEA blood coagulants market, by Country 2016 (%) 
Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis
Intended Audience:
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors
Research Methodology:
Source: National Center for Biotechnology Information, U.S. National Library of Medicine, U.S. Food and Drug Administration, National Institute of Standards and Technology, U.S. Department of Commerce, Eurostat, Cambridge University Hospitals, Directorate of Industries, Expert Interviews, Annual reports, White paper, Company Presentation, MRFR Analysis
Middle East & Africa Blood Coagulants Market Segmentation
The Middle East & Africa blood coagulants market is segmented on the basis of types, indications, and by country.
On the basis of types, the Middle East & Africa blood coagulants market is segmented into coagulation factor and others. Coagulation factor is further segmented into recombinant coagulation factor, plasma coagulation factor, and others.
On the basis of indication, the Middle East & Africa blood coagulants market is segmented into haemophilia, surgery, other bleeding disorders, and others. Haemophilia is further divided into haemophilia A and haemophilia B.
On the basis of country, the Middle East & Africa blood coagulants market is segmented into KSA, UAE, Qatar, Oman, Kuwait, Egypt, and Rest of Middle East & Africa.
Middle East & Africa Blood Coagulants Market Regional Analysis
The Middle East & Africa blood coagulants market is segmented on the basis of countries into Saudi Arabia (KSA), United Arab Emirates (UAE), Qatar, Oman, Kuwait, Egypt, and rest of Middle East & Africa. Saudi Arabia account for the largest market share of the Middle East & Africa blood coagulants market by countries in 2016. The large share is majorly attributed to increasing prevalence of the haemophilia disease in this country, high usage of the expensive recombinant coagulation factors for the treatment, and high disposable income of the population, and better healthcare facilities in this country.
Key Findings:
- Hemophilia segment dominates the market with nearly 45.5% share of the MEA market
- MEA coagulation factor market is projected to reach about USD 141.68 million by 2023
- MEA blood coagulants market for hemophilia segment was estimated to be USD 31.55 million in 2016
- UAE is the fastest growing region in the MEA blood coagulants market with 10.1% CAGR during 2017 to 2023
Key Players for Middle East & Africa Blood Coagulants Market
Some of the major players in Middle East & Africa blood coagulants market are:
- Pfizer Inc. (U.S.)
- Bayer AG (Germany)
- Novo Nordisk AS (Dernmark)
- Shire (Republic of Ireland)
- SOBI (Sweden)
- Octapharma (Switzerland)
- CSL Limited (Australia)
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
